{"article": [{"url": "https://www.marketwatch.com/story/palatins-stock-rises-on-plans-to-test-experimental-drug-as-covid-19-treatment-2020-06-23", "published": 1592900000.0, "headline": "Palatin's stock rises on plans to test experimental drug as COVID-19 treatment", "body": "Shares of Palatin Technologies Inc. PTN, +0.08% gained 31.8% in premarket trading on Tuesday after it said it would test one of its investigational drugs as a treatment for COVID-19. The drugmaker plans to submit an investigational new drug application in the third quarter of the year and initiate a Phase 2 randomized, controlled clinical trial for hospitalized adult COVID-19 patients with hypoxemic respiratory failure in the fourth quarter. The experimental therapy had previously gone through a Phase 1 clinical trial as a treatment for inflammatory bowel diseases, including ulcerative colitis. The company's stock is down 34.1% year-to-date, while the S&P 500 SPX, +0.87% has declined 3.5%."}]}